Company’s 36-month beta value is -1.10.Analysts have differing opinions on the stock, with 1 analysts rating it as a “buy,” 0 as “overweight,” 0 as “hold,” and 0 as “sell.”
The public float for SBFM is 1.22M, and currently, short sellers hold a 20.10% ratio of that floaft. The average trading volume of SBFM on September 25, 2024 was 158.65K shares.
3 Tiny Stocks Primed to Explode
The world's greatest investor — Warren Buffett — has a simple formula for making big money in the markets. He buys up valuable assets when they are very cheap. For stock market investors that means buying up cheap small cap stocks like these with huge upside potential.
We've set up an alert service to help smart investors take full advantage of the small cap stocks primed for big returns.
Click here for full details and to join for free
Sponsored
SBFM) stock’s latest price update
The stock price of Sunshine Biopharma Inc (NASDAQ: SBFM) has dropped by -9.28 compared to previous close of 3.34. Despite this, the company has seen a gain of 7.07% in its stock price over the last five trading days. accesswire.com reported 2024-09-04 that Current Test Positivity Rate for Coronavirus Infection in the U.S. is 18% Development of a novel antiviral compound, XR8-23 (Compound 10), targeting SARS-CoV-2 papain-like protease (PLpro) with both submicromolar potency and animal model efficacy XR8-23 (Compound 10) showed significant drug accumulation in lung of mice and favorable pharmacokinetic properties Research was conducted in collaboration with the University of Arizona FORT LAUDERDALE, FL / ACCESSWIRE / September 4, 2024 / Sunshine Biopharma, Inc. (NASDAQ:SBFM) (the “Company”), a pharmaceutical company offering and researching life-saving medicines in a variety of therapeutic areas including oncology and antivirals today announced the publication of new research results in the Journal of Medicinal Chemistry. The published data demonstrate a novel PLpro inhibitor with submicromolar potency and in vivo efficacy in a mouse model of SARS-CoV-2 infection.
SBFM’s Market Performance
SBFM’s stock has risen by 7.07% in the past week, with a monthly drop of -0.66% and a quarterly drop of -65.80%. The volatility ratio for the week is 15.11% while the volatility levels for the last 30 days are 7.80% for Sunshine Biopharma Inc The simple moving average for the past 20 days is 3.73% for SBFM’s stock, with a -97.99% simple moving average for the past 200 days.
SBFM Trading at -22.31% from the 50-Day Moving Average
After a stumble in the market that brought SBFM to its low price for the period of the last 52 weeks, the company was unable to rebound, for now settling with -99.59% of loss for the given period.
Volatility was left at 7.80%, however, over the last 30 days, the volatility rate increased by 15.11%, as shares surge +3.41% for the moving average over the last 20 days. Over the last 50 days, in opposition, the stock is trading -55.18% lower at present.
During the last 5 trading sessions, SBFM rose by +7.07%, which changed the moving average for the period of 200-days by -99.42% in comparison to the 20-day moving average, which settled at $2.93. In addition, Sunshine Biopharma Inc saw -99.44% in overturn over a single year, with a tendency to cut further losses.
Insider Trading
Reports are indicating that there were more than several insider trading activities at SBFM starting from Slilaty Steve N., who purchase 100,000 shares at the price of $0.10 back on Mar 04 ’24. After this action, Slilaty Steve N. now owns 130,000 shares of Sunshine Biopharma Inc, valued at $10,000 using the latest closing price.
Slilaty Steve N., the Chief Executive Officer of Sunshine Biopharma Inc, purchase 20,000 shares at $0.10 during a trade that took place back on Feb 08 ’24, which means that Slilaty Steve N. is holding 30,000 shares at $2,000 based on the most recent closing price.
Stock Fundamentals for SBFM
Current profitability levels for the company are sitting at:
- -0.14 for the present operating margin
- 0.3 for the gross margin
The net margin for Sunshine Biopharma Inc stands at -0.12. The total capital return value is set at -0.18. Equity return is now at value -15.79, with -12.75 for asset returns.
Based on Sunshine Biopharma Inc (SBFM), the company’s capital structure generated 0.02 points at debt to capital in total, while cash flow to debt ratio is standing at -18.9. The debt to equity ratio resting at 0.02. The interest coverage ratio of the stock is -36.39.
Currently, EBITDA for the company is -4.64 million with net debt to EBITDA at 2.79. When we switch over and look at the enterprise to sales, we see a ratio of -0.24. The receivables turnover for the company is 7.67for trailing twelve months and the total asset turnover is 1.04. The liquidity ratio also appears to be rather interesting for investors as it stands at 4.86.
Conclusion
In a nutshell, Sunshine Biopharma Inc (SBFM) has experienced a bad performance in recent times. The stock has received mixed “buy” and “hold” ratings from analysts. It’s important to note that the stock is currently trading at a significant distance from its 50-day moving average and its 52-week high.
